文献速递胸部肿瘤放疗

立体定向体部放疗治疗无法手术且不适合同步放化疗的III期非小细胞肺癌患者的疗效与毒性:一项回顾性研究

Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study.
PubMed 文献 · Radiat Oncol · 2023-08-24

本研究回顾性分析了2013年1月1日至2018年12月31日接受立体定向体部放疗(SBRT)的213例不可手术、不适合同步放化疗的III期非小细胞肺癌(NSCLC)患者,中位总生存期(OS)为36.5个月,中位无进展生存期(PFS)为16.1个月,13.1%患者出现≥3级毒性,中心型肿瘤患者中位OS较低(P<0.001),生物有效剂量(BED)不是OS的预测因素。

要点

  • 213例不可手术、不适合同步放化疗的III期NSCLC患者接受SBRT,中位OS为36.5个月,中位PFS为16.1个月。
  • 13.1%(28例)患者出现≥3级毒性,包括放射性肺炎9.4%(20例)和支气管肺出血3.8%(8例),无≥3级晚期毒性。
  • 中心型肿瘤患者较周围型患者中位OS更低(P<0.001),BED不是OS的预测因素。

核心结论

  • SBRT联合化疗治疗III期NSCLC可获得较好的治疗结局且毒性可接受。
  • 对于中心型肿瘤患者,可考虑适当降低BED。
  • 需进一步研究。

研究设计与样本

  • 回顾性研究,分析2013年1月1日至2018年12月31日接受SBRT的不可手术III期NSCLC患者。
  • 允许诱导化疗和巩固化疗。
  • 采用Kaplan-Meier法计算生存率和毒性,采用多因素Cox回归分析潜在危险因素。
  • 共纳入213例连续接受SBRT的患者。

主要发现

  • 中位OS为36.5个月,中位PFS为16.1个月。
  • 估计1年、2年、3年OS率分别为90.6%、73.7%、52.0%,相应PFS率分别为69.5%、25.4%、15.0%。
  • 治疗失败主要为远处转移(n=151,70.9%),局部复发率低(n=74,34.74%),区域复发率低(n=76,35.68%)。
  • 13.1%(n=28)患者出现≥3级毒性,包括放射性肺炎(n=20,9.4%)和支气管肺出血(n=8,3.8%)。
  • 无患者发生≥3级晚期毒性效应;与周围型肿瘤患者相比,中心型肿瘤患者中位OS更低(P<0.001),BED不是OS的预测因素。

临床怎么用

  • 作者认为SBRT联合化疗治疗III期NSCLC可获得较好的治疗结局且毒性可接受。
  • 作者认为对于中心型肿瘤患者,可考虑适当降低BED。
  • 作者指出需进一步研究。

局限性

  • 需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In this study, we evaluated the efficacy and toxicity of stereotactic body radiotherapy (SBRT) as replacement strategy of conventionally fractionated radiation therapy in stage III non-small cell lung cancer (NSCLC) patients unfit for concurrent chemoradiation therapy (CRT). METHODS: We analyzed the clinical outcomes in patients with unresectable stage III NSCLC who received SBRT from January 1, 2013 to December 31, 2018. Both induction and consolidation chemotherapy were allowed. The survival rates and toxicities were calculated using the Kaplan-Meier method, and potential risk factors were investigated by multivariate Cox regression. RESULTS: A total of 213 consecutive patients who had received SBRT were enrolled. The median overall survival (OS) and progression-free survival (PFS) were 36.5 months and 16.1 months respectively. The estimated 1-, 2- and 3-year OS rates were 90.6%, 73.7% and 52.0%, respectively and the corresponding PFS rates were 69.5%, 25.4% and 15.0%, respectively. Treatment failures were largely (n = 151, 70.9%) distant metastases, with low rates of local (n = 74, 34.74%) and regional (n = 76, 35.68%) recurrences. In 13.1% patients (n = 28), ≥ grade (G) 3 toxicities were identified, including radiation pneumonia (n = 20, 9.4%) and bronchopulmonary hemorrhage (n = 8, 3.8%). None of the patients suffered from ≥ G 3 late toxic effects. Compared with patients with peripheral tumors, patients with central tumors had lower median OS (P<0.001) and the biological effective dose (BED) was not a predictor for OS. CONCLUSIONS: SBRT combined with chemotherapy for stage III NSCLC produced favorable treatment outcomes with acceptable toxicity. For patients with central tumors, an appropriate BED reduction can be considered. Further studies are warranted. TRIAL REGISTRATION: Retrospectively registered.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jia Z, Fang F, Cao Y, et al. Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study. Radiat Oncol. 2023. PMID: 37620952. doi:10.1186/s13014-023-02333-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。